FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556616215> ?p ?o ?g. }

• W2556616215 abstract "Abstract Abstract 3152 Poster Board III-89 Human parvovirus B19 (B19V), a small non-enveloped virus, is the causative agent of the childhood disease erythema infectiosum (fifth disease) but causes, especially when the disease occurs during adulthood, a number of clinical symptoms as arthralgia, arthritis, (transient) aplastic crisis, anaemia, and hydrops fetalis (during pregnancy). B19V is normally spread via the respiratory route, however, parenteral transmission can occur through blood or blood components and plasma-derived products. In order to demonstrate the safety of plasma-derived products regarding B19V, virus validation studies are performed, using usually animal parvoviruses as models for B19V which indicate that this virus is highly resistant to commonly used inactivation methods as heat. Employing a cell culture infectivity assay for B19V, established at CSL Behring's virology laboratory, a considerable higher sensitivity of B19V to pasteurization (heat treatment in aqueous solution at 60°C for 10 hours) could be demonstrated for B19V in contrast to the animal parvovirus CPV (canine parvovirus). B19V was not only very sensitive to heat in unstabilised product intermediates but also heat sensitive when studying intermediates of various plasma products containing high concentrations of the stabilizers sucrose and glycine. Although these protein stabilizers had also a stabilizing effect on B19V this virus was nevertheless considerably more sensitive to pasteurization than CPV. As shown below, pasteurization results in an effective inactivation of B19V in a wide range of plasma-derived products. Product Mean Virus Reduction Factor [log10] due to Pasteurization B19V CPV VWF / FVIII (Humate-P) ≥3.9 1.1 FVIII (Beriate P) a ≥3.8 0.7 Fibrinogen (RiaSTAP) b ≥4.5 1.6 PCC (Beriplex P/N) a 3.5 0.5 C1-INH (Berinert P) a 3.9 1.4 Human Thrombin a 3.5 0.5 FXIII (Fibrogammin P) a ≥4.0 1.0 scIG (Vivaglobin) ≥5.0c 2.3 Human albumin (different products) ≥4.3 1.6 a product not licensed in USA b Pasteurization time 20 hours c studied in a porcine immunoglobulin intermediate to avoid neutralization by human IgG Based on these experimental data on inactivation of B19V by pasteurization and a plasma pool for fractionation not exceeding 104 IU B19V DNA/ml, the virus safety of plasma-derived products regarding B19V can be assessed more correctly demonstrating an appropriate margin of safety. Disclosures Groener: CSL Behring: Employment. Nowak:CSL Behring: Employment. Schäfer:CSL Behring: Employment." @default.
• W2556616215 created "2016-11-30" @default.
• W2556616215 creator A5030570962 @default.
• W2556616215 creator A5033972829 @default.
• W2556616215 creator A5062895400 @default.
• W2556616215 date "2009-11-20" @default.
• W2556616215 modified "2023-10-01" @default.
• W2556616215 title "Parvovirus B19 Is Inactivated by Pasteurization, a Dedicated Virus Inactivation Step in the Manufacturing Process of Plasma-Derived Products." @default.
• W2556616215 doi "https://doi.org/10.1182/blood.v114.22.3152.3152" @default.
• W2556616215 hasPublicationYear "2009" @default.
• W2556616215 type Work @default.
• W2556616215 sameAs 2556616215 @default.
• W2556616215 citedByCount "1" @default.
• W2556616215 crossrefType "journal-article" @default.
• W2556616215 hasAuthorship W2556616215A5030570962 @default.
• W2556616215 hasAuthorship W2556616215A5033972829 @default.
• W2556616215 hasAuthorship W2556616215A5062895400 @default.
• W2556616215 hasConcept C109097599 @default.
• W2556616215 hasConcept C159047783 @default.
• W2556616215 hasConcept C185592680 @default.
• W2556616215 hasConcept C203014093 @default.
• W2556616215 hasConcept C2522874641 @default.
• W2556616215 hasConcept C2776668709 @default.
• W2556616215 hasConcept C2778561560 @default.
• W2556616215 hasConcept C2779630601 @default.
• W2556616215 hasConcept C31903555 @default.
• W2556616215 hasConcept C86803240 @default.
• W2556616215 hasConceptScore W2556616215C109097599 @default.
• W2556616215 hasConceptScore W2556616215C159047783 @default.
• W2556616215 hasConceptScore W2556616215C185592680 @default.
• W2556616215 hasConceptScore W2556616215C203014093 @default.
• W2556616215 hasConceptScore W2556616215C2522874641 @default.
• W2556616215 hasConceptScore W2556616215C2776668709 @default.
• W2556616215 hasConceptScore W2556616215C2778561560 @default.
• W2556616215 hasConceptScore W2556616215C2779630601 @default.
• W2556616215 hasConceptScore W2556616215C31903555 @default.
• W2556616215 hasConceptScore W2556616215C86803240 @default.
• W2556616215 hasLocation W25566162151 @default.
• W2556616215 hasOpenAccess W2556616215 @default.
• W2556616215 hasPrimaryLocation W25566162151 @default.
• W2556616215 hasRelatedWork W147696375 @default.
• W2556616215 hasRelatedWork W1551995404 @default.
• W2556616215 hasRelatedWork W1742939097 @default.
• W2556616215 hasRelatedWork W1906026319 @default.
• W2556616215 hasRelatedWork W1975928061 @default.
• W2556616215 hasRelatedWork W1984634112 @default.
• W2556616215 hasRelatedWork W2028960107 @default.
• W2556616215 hasRelatedWork W2057751998 @default.
• W2556616215 hasRelatedWork W2065993360 @default.
• W2556616215 hasRelatedWork W2072951090 @default.
• W2556616215 hasRelatedWork W2076281028 @default.
• W2556616215 hasRelatedWork W2079566602 @default.
• W2556616215 hasRelatedWork W2081639027 @default.
• W2556616215 hasRelatedWork W2123468629 @default.
• W2556616215 hasRelatedWork W2163361432 @default.
• W2556616215 hasRelatedWork W2417790589 @default.
• W2556616215 hasRelatedWork W2549326549 @default.
• W2556616215 hasRelatedWork W2565039539 @default.
• W2556616215 hasRelatedWork W2588418932 @default.
• W2556616215 hasRelatedWork W3029578808 @default.
• W2556616215 isParatext "false" @default.
• W2556616215 isRetracted "false" @default.
• W2556616215 magId "2556616215" @default.
• W2556616215 workType "article" @default.